144 related articles for article (PubMed ID: 34229245)
1. Binding and antiplatelet activity of quercetin, rutin, diosmetin, and diosmin flavonoids.
Zaragozá C; Monserrat J; Mantecón C; Villaescusa L; Álvarez-Mon MÁ; Zaragozá F; Álvarez-Mon M
Biomed Pharmacother; 2021 Sep; 141():111867. PubMed ID: 34229245
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet activity of flavonoid and coumarin drugs.
Zaragozá C; Monserrat J; Mantecón C; Villaescusa L; Zaragozá F; Álvarez-Mon M
Vascul Pharmacol; 2016 Dec; 87():139-149. PubMed ID: 27616636
[TBL] [Abstract][Full Text] [Related]
3. Flavonoids: Antiplatelet Effect as Inhibitors of COX-1.
Zaragozá C; Álvarez-Mon MÁ; Zaragozá F; Villaescusa L
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164411
[TBL] [Abstract][Full Text] [Related]
4. Potential Therapeutic Anti-Inflammatory and Immunomodulatory Effects of Dihydroflavones, Flavones, and Flavonols.
Zaragozá C; Villaescusa L; Monserrat J; Zaragozá F; Álvarez-Mon M
Molecules; 2020 Feb; 25(4):. PubMed ID: 32102475
[TBL] [Abstract][Full Text] [Related]
5. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
Berny-Lang MA; Jakubowski JA; Sugidachi A; Barnard MR; Michelson AD; Frelinger AL
J Am Heart Assoc; 2013 May; 2(3):e000026. PubMed ID: 23676293
[TBL] [Abstract][Full Text] [Related]
6. Human platelet activation is inhibited by the occupancy of glycoprotein IIb/IIIa receptor.
Padoin E; Alexandre A; Cavallini L; Polverino de Laureto P; Rao GH; Doni MG
Arch Biochem Biophys; 1996 Sep; 333(2):407-13. PubMed ID: 8809080
[TBL] [Abstract][Full Text] [Related]
7. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase.
Kang WS; Chung KH; Chung JH; Lee JY; Park JB; Zhang YH; Yoo HS; Yun YP
J Cardiovasc Pharmacol; 2001 Dec; 38(6):875-84. PubMed ID: 11707691
[TBL] [Abstract][Full Text] [Related]
9. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
10. Endothelial cells microparticle-associated protein disulfide isomerase promotes platelet activation in metabolic syndrome.
Fan GQ; Qin RR; Li YH; Song DJ; Chen TS; Zhang W; Zhong M; Zhang Y; Xing YQ; Wang ZH
Oncotarget; 2016 Dec; 7(50):83231-83240. PubMed ID: 27825126
[TBL] [Abstract][Full Text] [Related]
11. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF
Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets.
Sheu JR; Hsiao G; Chou PH; Shen MY; Chou DS
J Agric Food Chem; 2004 Jul; 52(14):4414-8. PubMed ID: 15237945
[TBL] [Abstract][Full Text] [Related]
14. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
15. Can the antiplatelet effects of cangrelor be reliably studied in mice under in vivo and in vitro conditions using flow cytometry?
Kassassir H; Siewiera K; Sychowski R; Watała C
Pharmacol Rep; 2013; 65(4):870-83. PubMed ID: 24145081
[TBL] [Abstract][Full Text] [Related]
16. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
[TBL] [Abstract][Full Text] [Related]
19. MK-383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor.
Barlage S; Wimmer A; Pfeiffer A; Rothe G; Schmitz G
Platelets; 2002 May; 13(3):133-40. PubMed ID: 12180495
[TBL] [Abstract][Full Text] [Related]
20. [Mechanisms of platelet activation and development of antiplatelet agents].
Cazenave JP; Gachet C; Lanza F
Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1501-6. PubMed ID: 9092410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
